Protalix/Pfizer first in US with plant cell-based recombinant therapeutic protein
This article was originally published in Scrip
For Protalix BioTherapeutics and Pfizer, the US FDA's 1 May marketing clearance of Elelyso (taliglucerase alfa), an enzyme replacement therapy (ERT) for Gaucher disease, puts the firms in the record books for gaining the first US approval of a recombinant therapeutic protein made in a plant organism – carrot cells, to be exact.
You may also be interested in...
Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.